Block­buster can­cer drug Calquence hits pri­ma­ry end­point in tri­al for first-line man­tle cell lym­phoma

As­traZeneca is work­ing on mov­ing its BTK in­hibitor Calquence in­to ear­li­er stages of man­tle cell lym­phoma, re­leas­ing what it calls pos­i­tive in­ter­im re­sults from a Phase 3 tri­al.

The com­bo of Calquence with chemother­a­py and im­munother­a­py led to an in­crease in pro­gres­sion-free sur­vival, com­pared with chemother­a­py and im­munother­a­py alone, As­traZeneca said in a press re­lease. It didn’t pro­vide da­ta on the PFS re­sults, the tri­al’s pri­ma­ry end­point, but called them “sta­tis­ti­cal­ly sig­nif­i­cant and clin­i­cal­ly mean­ing­ful.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER